Realtime | Geld | Brief | Zeit |
---|---|---|---|
3,810 | 3,930 | 28.03. | |
0,000 | 0,000 | 28.03. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC | 5 | GlobeNewswire (USA) | ||
13.03. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 10 | GlobeNewswire (USA) | ||
11.03. | Intelligent Bio Solutions Announces $10.1 Mln Private Placement | 2 | RTTNews | ||
11.03. | Intelligent BIO Ekes up on Private Placement | 8 | Baystreet.ca | ||
11.03. | Intelligent Bio Solutions secures $10.1 million in private placement | 4 | Investing.com | ||
11.03. | Intelligent Bio Solutions announces $10M private placement priced at-the-market under Nasdaq rules | 2 | Seeking Alpha | ||
11.03. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
06.03. | Peering Into Intelligent Bio Solutions' Recent Short Interest | 9 | Benzinga.com | ||
01.03. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024 | 15 | GlobeNewswire (USA) | ||
29.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 6 | SEC Filings | ||
28.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway | 333 | GlobeNewswire (Europe) | NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
20.02. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 16 | SEC Filings | ||
19.02. | Peering Into Intelligent Bio Solutions' Recent Short Interest | 8 | Benzinga.com | ||
16.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders' Equity Requirement | 231 | GlobeNewswire (Europe) | NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
12.02. | Why Is Intelligent Bio Solutions (INBS) Stock Down 24% Today? | 31 | InvestorPlace | ||
09.02. | Intelligent Bio Solutions GAAP EPS of -$2.07 beats by $1.17, revenue of $0.76M misses by $0.25M | 21 | Seeking Alpha | ||
09.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights | 372 | GlobeNewswire (Europe) | - Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 - - Expanded into New Zealand market and increased market share in existing... ► Artikel lesen | |
09.02. | INTELLIGENT BIO SOLUTIONS INC. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
05.02. | Why Is Intelligent Bio Solutions Stock Tumbling Today? | 21 | Benzinga.com | ||
05.02. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds | 15 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
DRAEGERWERK | 50,90 | -0,39 % | HAUCK AUFHÄUSER INVESTMENT BANKING stuft Draegerwerk auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking hat die Einstufung für Drägerwerk auf "Buy" mit einem Kursziel von 65 Euro belassen. Sollte das Sicherheitsgeschäft ausgegliedert werden... ► Artikel lesen | |
TELADOC HEALTH | 14,055 | +0,36 % | Here's Why Investors Should Hold Teladoc (TDOC) Stock Now | ||
ROKU | 60,35 | +0,13 % | This Is What Whales Are Betting On Roku | ||
BICO GROUP | 4,078 | +0,57 % | Schock-News für Bico Group Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
EUROFINS SCIENTIFIC | 59,00 | +0,17 % | Eurofins: Purchases of Own Shares from the 18th to the 22th of March 2024 | Regulatory News:
Eurofins (Paris:ERF):
Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total... ► Artikel lesen | |
SERNOVA | 0,382 | +2,36 % | Sernova gibt Entwicklungen im Management bekannt | London, Ontario und Boston, Massachusetts, den 11. März 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FWB/XETRA: PSH), ein in der klinischen Phase befindliches Unternehmen, das sich auf
die... ► Artikel lesen | |
SYNLAB | 10,950 | +0,55 % | SYNLAB unter Druck: Dividendenstopp, Corona-Schock, Komplettübernahme | Europas größte Laborkette, SYNLAB, hat am Montagmorgen sein Jahresergebnis präsentiert. Sicherlich hätten die Münchner gerne andere Zahlen ihren Anlegern vorgelegt.Steigende Kosten und sinkende Covid-Testnachfrage... ► Artikel lesen | |
ALIGN TECHNOLOGY | 303,20 | -0,21 % | Here's Why You Should Buy Align Technology (ALGN) Stock Now | ||
HIMS & HERS HEALTH | 14,200 | -1,05 % | Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth... ► Artikel lesen | |
NUGEN MEDICAL DEVICES | 0,081 | +2,53 % | NuGen Medical: Regierungsentscheidung löst Rallye aus? | ||
PLUS THERAPEUTICS | 1,676 | -0,48 % | Plus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | Began enrollment of the 5th of an anticipated 7 planned dosing cohorts for the ReSPECT-LM Phase 1 dose escalation trial with rhenium (186Re) obisbemeda for leptomeningeal metastases (LM) Reached agreement... ► Artikel lesen | |
INVITAE | 0,110 | 0,00 % | Invitae Corporation: Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit... ► Artikel lesen | |
SPINEWAY | 1,480 | -7,50 % | SPINEWAY: 2023 Shareholders General Meeting | ||
ATOSSA THERAPEUTICS | 1,706 | +4,28 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient | SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human... ► Artikel lesen | |
EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 | -- Third Consecutive Year of Phexxi Net Sales Growth --
-- Total Operating Expense Reduced 64% from 2022 Levels --
-- Sales and marketing expense as a percentage of net sales was 54% for the fourth... ► Artikel lesen |